<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288885</url>
  </required_header>
  <id_info>
    <org_study_id>1941-CL-0001</org_study_id>
    <secondary_id>2006-002719-28</secondary_id>
    <nct_id>NCT01288885</nct_id>
  </id_info>
  <brief_title>First in Men Study of Single Oral Doses of ASP1941 in Healthy Subjects</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Dose Escalating Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food-effect of Single Oral Doses of ASP1941 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study determined the safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics
      (PD) of ASP1941 after a single oral dose (Part A). In addition, it was investigated whether
      the intake of food had an effect on the PK of ASP1941 (Part B).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of two parts. Part A is a double-blind, placebo controlled single dose
      escalation study to evaluate the safety and tolerability of single ascending doses of
      ASP1941. Part B is an open label, crossover design food-effect study to evaluate the effect
      of fed conditions on the PK of ASP1941.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability assessed by the incidence of adverse events, vital signs, physical examinations, 12-lead ECG and lab-tests</measure>
    <time_frame>Up to 2 weeks after each administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics calculated by ASP1941 plasma concentration change</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics assessed by ASP1941 glucose concentration changes in blood and urine</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">76</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1941</intervention_name>
    <description>Oral</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight between 60-100 kg, body mass index (BMI) between 20-30 kg/m2, inclusive

        Exclusion Criteria:

          -  Fasting Plasma Glucose (FPG) &gt; 6.4 mmol/l

          -  HbA1c &gt; 6.2%

          -  Pulse &lt;40 or &gt;90 beats per minute; Systolic Blood Pressure (SBP) &lt;90 or &gt;140 mmHg;
             Diastolic Blood Pressure (DBP) &lt;40 or &gt;95mmHg
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M15 6SH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2011</study_first_posted>
  <last_update_submitted>February 1, 2011</last_update_submitted>
  <last_update_submitted_qc>February 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Disclosure Office Europe</name_title>
    <organization>Astellas Pharma Europe BV</organization>
  </responsible_party>
  <keyword>ASP1941</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>First in Men</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

